Next Article in Journal
Compilation and Analysis of Web-Based Orthopedic Personalized Predictive Tools: A Scoping Review
Next Article in Special Issue
Biomarker Development for Metastatic Renal Cell Carcinoma: Omics, Antigens, T-cells, and Beyond
Previous Article in Journal
Fluid Candidate Biomarkers for Alzheimer’s Disease: A Precision Medicine Approach
Previous Article in Special Issue
Targeted Therapy Recommendations for Therapy Refractory Solid Tumors—Data from the Real-World Precision Medicine Platform MONDTI
Review

Imaging Biomarkers of Tumour Proliferation and Invasion for Personalised Lung Cancer Therapy

1
Faculty of Informatics and Science, University of Oradea, 410087 Oradea, Romania
2
Cancer Research Institute, University of South Australia, Adelaide, SA 5001, Australia
J. Pers. Med. 2020, 10(4), 222; https://doi.org/10.3390/jpm10040222
Received: 7 October 2020 / Revised: 3 November 2020 / Accepted: 10 November 2020 / Published: 12 November 2020
(This article belongs to the Special Issue Personalized Medicine in Oncology)
Personalised treatment in oncology has seen great developments over the last decade, due to both technological advances and more in-depth knowledge of radiobiological processes occurring in tumours. Lung cancer therapy is no exception, as new molecular targets have been identified to further increase treatment specificity and sensitivity. Yet, tumour resistance to treatment is still one of the main reasons for treatment failure. This is due to a number of factors, among which tumour proliferation, the presence of cancer stem cells and the metastatic potential of the primary tumour are key features that require better controlling to further improve cancer management in general, and lung cancer treatment in particular. Imaging biomarkers play a key role in the identification of biological particularities within tumours and therefore are an important component of treatment personalisation in radiotherapy. Imaging techniques such as PET, SPECT, MRI that employ tumour-specific biomarkers already play a critical role in patient stratification towards individualized treatment. The aim of the current paper is to describe the radiobiological challenges of lung cancer treatment in relation to the latest imaging biomarkers that can aid in the identification of hostile cellular features for further treatment adaptation and tailoring to the individual patient’s needs. View Full-Text
Keywords: biomarkers; molecular imaging; non-small cell lung cancer; proliferation; cancer stem cells; circulating tumour cells; personalised treatment biomarkers; molecular imaging; non-small cell lung cancer; proliferation; cancer stem cells; circulating tumour cells; personalised treatment
Show Figures

Graphical abstract

MDPI and ACS Style

Marcu, L.G. Imaging Biomarkers of Tumour Proliferation and Invasion for Personalised Lung Cancer Therapy. J. Pers. Med. 2020, 10, 222. https://doi.org/10.3390/jpm10040222

AMA Style

Marcu LG. Imaging Biomarkers of Tumour Proliferation and Invasion for Personalised Lung Cancer Therapy. Journal of Personalized Medicine. 2020; 10(4):222. https://doi.org/10.3390/jpm10040222

Chicago/Turabian Style

Marcu, Loredana G. 2020. "Imaging Biomarkers of Tumour Proliferation and Invasion for Personalised Lung Cancer Therapy" Journal of Personalized Medicine 10, no. 4: 222. https://doi.org/10.3390/jpm10040222

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop